Sunyoung Jang

Title: Sunyoung Jang - Innovator in CD19 Binding Molecules

Introduction

Sunyoung Jang is an accomplished inventor based in Cambridge, MA, USA. He holds a notable patent that contributes to the field of medical research, specifically in the development of therapeutic molecules targeting CD19.

Latest Patents

Sunyoung's patent involves the discovery of CD19 binding molecules that are designed to specifically bind to the CD19 antigen. This patent, titled "CD19 binding molecules and uses thereof," encompasses monospecific, bispecific, and trispecific binding molecules. The invention includes conjugates that incorporate these binding molecules and pharmaceutical compositions that utilize them. Additionally, it details methods to treat diseases and disorders linked to CD19 expression, along with the creation of recombinant host cells engineered to produce these molecules efficiently through controlled culturing.

Career Highlights

Currently, Sunyoung is employed at Novartis AG, a global healthcare company known for its innovative approaches to medicine. His work focuses on advancing the therapeutic applications of CD19 binding molecules, which hold significant promise in treating various immune-related diseases, particularly in oncology.

Collaborations

In his endeavors, Sunyoung collaborates closely with his colleague, Amy Rayo. Together, they contribute to the research and development of groundbreaking therapies, amplifying the impact of their work at Novartis AG.

Conclusion

Sunyoung Jang’s contributions to the field of biomedicine through his patent on CD19 binding molecules signify a crucial step toward innovative treatments for diseases associated with CD19 expression. His ongoing work at Novartis AG, in collaboration with talented peers like Amy Rayo, continues to push the boundaries of medical science, offering hope for more effective therapeutic options in the future.